{"name":"Xenon Pharmaceuticals Inc.","slug":"xenon-pharmaceuticals-inc","ticker":"","exchange":"","domain":"xenon-pharma.com","description":"","hq":"Burnaby","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"XEN1101","genericName":"XEN1101","slug":"xen1101","indication":"Treatment of trigeminal neuralgia","status":"phase_3"},{"name":"14C-XEN1101","genericName":"14C-XEN1101","slug":"14c-xen1101","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"XEN1101","genericName":"XEN1101","slug":"xen1101","phase":"phase_3","mechanism":"XEN1101 is a selective Nav1.7 sodium channel blocker.","indications":["Treatment of trigeminal neuralgia"],"catalyst":""},{"name":"14C-XEN1101","genericName":"14C-XEN1101","slug":"14c-xen1101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE16RGJIRGhaUkt5X095WHlweFhCTE02dU1POVI5dWY1QVJPRmJWemgxaUtHOUZsX2tOREgyaVhyRGRIYnJ2bXFweUMzTVBMbnVsTmtiNG5WdnlrZ3U1MHI5Tl9LbkxGYkNpSjR6TTRBVFY3S1VNUmFubXlkWTg?oc=5","date":"2026-03-28","type":"pipeline","source":"AOL.com","summary":"Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com","headline":"Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPalF4RnBqQlU5MEp5MWtma21jdnN5ZFJNZ0tMUmtScTF6VEtDXzJGQ0kxbHdNT1dmSHlNczlnMHoyVjNSV2hGMWNPMjVqbF84cktDcnJPRElmdVluQXdaQkZqOU4yekhqRmlmVFZUeVBVMHJjZExHVUY1aEJmamtlTnhiT1ZGeGl3bVlpekNWckxJcmt5NF9jUmVGQk15S0ZlbUtLMGNqZWktaGY1NlY3Y2VVa1ZUNGY1eDFodmhURUVHNzNKMFNucXdkNEMybVZOM2VKM2VWTFpDUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"The Motley Fool","summary":"Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool","headline":"Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWjFPVUI3R1pOSWMxUHM4aHRvUUZkV3U5b05UbHZSZ3ljdGNjNjBxYXhiQklNTHlKM3FfMEN6dGRmMUJOT2R2UlJYTFZRZTZLOC1YT2xzOWNDWEdzZ0tEWkxTN3NFTktSV19oTHRLVFlTTnVSSWs0cXlOQk1QekVzSmg0LVhvNnZ0bzd0LVVmbDRwX2M0a2hrMHUydEhGcWY2bHVWbFVMeGp0eUpkX1A4SXJMZjVRbmpORTVJ?oc=5","date":"2026-03-10","type":"pipeline","source":"Stock Titan","summary":"Biotech Xenon raises $650M in stock sale at $57 a share - Stock Titan","headline":"Biotech Xenon raises $650M in stock sale at $57 a share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNVQyZUFuNVQxV1VrbFZLRlllZkI5bjdfQzU5bjJGSk05M21OZW55Zk1pX29JUjAtWlBzQzhZX1VrVEJwYlN0QXBDWk8wT2o5YXI3ZHZTbDd0Slg2YXhXbmk0WjctVmlmdzRYY1lfZEJjVlZyamVKUlh0cnNMbDZwblFOdDAyWmltX3pzcDhXckZsRU85QTdIQWRpNVRzSjlzN0dWM1dGQ3lWUQ?oc=5","date":"2026-03-09","type":"trial","source":"seekingalpha.com","summary":"Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE) - seekingalpha.com","headline":"Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPMlYwZ09XMHhpRmVEcFRId01fWGh6QlFjR204NDZoTm9OS3ZIUWJYSmNrQnRWMWlJZmcyUTB0NFhNVVFKRUp1b1k2c1JWbTE4S3FPb2I4NC1vQ0FnSVhQZ2dQa1UxYjRiV3FZT2xBTWV0aTFRdmN3TjRmLW8zVm5WR2gtTjZON29jM2xGbUZPbmRrNHNFQkM5bUtzcU1oS09OS1FnTHljR1VNcFcyd2hfYXlkREJoZ2hYMVBzUU1aV3hzWWdHd2x3?oc=5","date":"2026-03-09","type":"pipeline","source":"globenewswire.com","summary":"Xenon Pharmaceuticals Announces Proposed Public Offering - globenewswire.com","headline":"Xenon Pharmaceuticals Announces Proposed Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOc3NrcEx6RUMxdUw3UFNLR2pVRnEydmlOV2hYLVVwM0paRFFnY21EQ1JEMm1UQVRjUXFqVW5udkRza0tJUFJpZVZMblhiVGU2X0pRNndjVGMzSEU4cnBEbGVyUWZWanpZeEVHbWRsVGF5c2ExSFhLX3JHbnhqNHlVMkg1Y0VYOTdNMlVDbDZWNm5kaEMtS0FfUElJd3BVUV9tNUUxQQ?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"$500M stock sale: neuroscience drug maker Xenon tests market appetite - Stock Titan","headline":"$500M stock sale: neuroscience drug maker Xenon tests market appetite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQZ2tFRmVWUFRZS3ltVTg2cnVxTjIwRHBmVTdzeEhkdHdpVUtzN0VENGpVZXpQV0RwcU1jdVVORjRUVHhmcWkwMWZ2YUJXN2VtdVktSXVCVGZhRkNCZ0lXVVFkMlFqSG5nOHJFZ1RLUDBqc2ZKb01NeTh0cTh3OWdzYjhuTUJXWmFoYzJyc1VlRGN0UEwwd1pZNG9qUl9QeGxzQ25SU2dKdHBleXVFSVkxOTBvRGdYbkZydzRnMDJNMmFyRlVNcVE5RW9EdFp1V1pTczVrbmVmREN2MWNHamFMUUNDS1JvZXdvY2E1eWxYYkM3aVFfVHZGVjFIcE41aGQyaDE4MTl0eHpwY2lCNm5SOFg3aHgwckgwVDJmdFFqRTRieUpH?oc=5","date":"2026-03-08","type":"trial","source":"globenewswire.com","summary":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 - globenewswire.com","headline":"Xenon to Announce Topline Results from Phase 3 X-TOLE2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxONG1OLUhiT0VNNXQtZ0xyZzBlU00zZkp5dmlLdUlZUjVjQlphQUdqLWFqX2IyUGhoREZFX2NYY1lnbkZEcTlKdmE1MUFVVkdMLTZIdjZwZHYzZUZ2ZzdKTVJNVGVvSDhIVTNmSU9SNlc0dUppSkZYZzVaY2YxS3hRNnRGTmxscG1hYmQ0VGhONjBJOVJ1YjJQenM2cXRZZGVHVktPVEhIZzBfb3NmUkpMYkJiSm80RGZOa21kdA?oc=5","date":"2026-03-01","type":"regulatory","source":"The Globe and Mail","summary":"Xenon awaiting critical epilepsy drug study results that could lead to FDA approval - The Globe and Mail","headline":"Xenon awaiting critical epilepsy drug study results that could lead to FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOa3FoeGRUM1NVd0RWTTA5VlpsVzFZbVVQZEYtTS00YWliekF0U0R5V2pKOUtpS0FiaHJYdFpfdFZKWEg0YkIxX2xxM2Zva280R3IwVFZBNF9XS1Z3ZTBDNjBpcUl4Vzk1UWxSNXBjN2FiSVVRLWtHQzh0NUh6Y0tUY0J1TDI0WWh2WnhldWJaLVFDamtsS2ZPYw?oc=5","date":"2026-02-12","type":"trial","source":"RTTNews","summary":"Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews","headline":"Xenon Pharma To Report Epilepsy Trial Results Next Month","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNNmlpaWlZUkkzcHQ0Y0RQc2lTdFZPVkM3MmNlUzVzX21RWmoxaTlWbGRkQnE2Z1B6dWRPazQ4RUktOXNjUzI1aVdDX3N1bW1ubWpramRXREVXMmZacVkxWk9kV0JBaS1rSnBTOXhGUllKU1lJZUttcEpUVXRZRTl5MVYwTjBhR0Fwb2Q1bEI3ckt4WXBsbUJsZXNkVlM4U0RDLWg4LWMzVHVqcE5tQ1V3VjZ0cURjRmdzbFhiN2xNNFNBS0tVYWd1ckNaQ3gwaXhY?oc=5","date":"2026-01-05","type":"pipeline","source":"Quiver Quantitative","summary":"Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative","headline":"Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdWFjSms4YllueTRzeGVIUnM5anp4N0dDNVRJbU9aSTFNb21uVEpTc19jRTJyYTRrLVVPNXNfcGwzdTlfWTBtV3c3SUFncFZraXpwX3FaSU9pTi1QdFB4VktTeWlab1MzTnBpeGFaNVgzYktSR05hUHFQeHI5dWtkS2JpY1Zob3VyeEYwMXlmdXlwUkpMenlhaE9CVGRDaWd5eC02TWQ2cXVNWU85bHR6SS1ENXFUYjJmLTZz?oc=5","date":"2025-12-18","type":"trial","source":"seekingalpha.com","summary":"Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - seekingalpha.com","headline":"Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPcW43SENKMjBicGJTTkJJcTRvdmZJUnEyN1dnTkNUTmhES21obW5Nb1VhQjhkWUktbmdkR25fYTh2cGR3V1pwZTViZDFyX0dEMmJYdGJySEw2RHJ0QnY2c284WHc0MVhnVnRHNEpVN2c4aVJHWkNsR0tMSWNrRU5Wb3dPLUptSXFnMHVycmMzOW5wQTJxOEliNDhNWVlCbVJTTXBndDY2UjNPM0xzOGJzWjNTNUE5QTUtTWNQSmtTN1IxUzdOTHEycllQa2o?oc=5","date":"2025-12-05","type":"pipeline","source":"Quiver Quantitative","summary":"Xenon Pharmaceuticals Reports Significant Long-Term Efficacy of Azetukalner in Epilepsy at AES 2025 - Quiver Quantitative","headline":"Xenon Pharmaceuticals Reports Significant Long-Term Efficacy of Azetukalner in Epilepsy at AES 2025","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}